For example, cetuximab and bevacizumab, existing effects in impairing tumor vasculature by blocking EGFR and VEGF, respectively, have been approved by the US Food and Drug Administration (FDA) and commercially applied in treatment of metastatic cancers [47,48]. This evidence concerns the gene VEGFA and metastatic malignant neoplasm.